# Bellerophon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bellerophon-therapeutics

- Industry: Biotechnology
- Headquarters: Warren, US
- Website: www.bellerophon.com
- Total disclosed funding: $80M
- Latest round: Series A (Dec 26, 2013)
- Investors on record: 5

## About

Bellerophon Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapies for serious respiratory and cardiovascular diseases, focusing on advanced drug delivery systems to enhance treatment effectiveness.Founded in 2014 and headquartered in Warren, US, Bellerophon Therapeutics Inc. specializes in therapeutic solutions for respiratory conditions. The company has raised a total of USD 5.00 mn through various funding rounds, the latest being a PIPE round amounting to USD 5.00 mn. The firm has completed 8 deals to date. The leadership team includes CEOs Fabian Tenenbaum and Peter Fernandes.Bellerophon focuses on developing innovative therapeutic solutions aimed at addressing serious respiratory and cardiovascular diseases. Its core product offering includes proprietary drug delivery systems designed to enhance the efficacy and safety of existing treatments, targeting conditions such as pulmonary hypertension. The primary end users are patients, healthcare providers, and specialty pharmacies that facilitate access to these therapies. Bellerophon’s solutions are marketed across North America and select regions in Europe.Bellerophon generates revenue through the commercialization of specialized therapeutic products, primarily engaging in B2B transactions with healthcare institutions and specialized distributors. Revenue is derived from long-term supply agreements and direct sales to hospitals and clinics, structured to meet the needs of healthcare providers. In the most recent year, the company reported an EBITDA of USD -22.32 mn.Bellerophon plans to expand its product offerings by designing and launching new therapeutic solutions targeting unmet medical needs in respiratory and cardiovascular diseases. The company aims to enter new geographic markets in Europe and expand its presence in North America by 2025. The recent PIPE funding of USD 5.00 mn will be utilized to support these initiatives, including the potential launch of new products. In February 2015, Bellerophon raised USD 60 mn in an IPO, which has been instrumental in supporting its growth trajectory.

## Funding rounds

- Series A, Dec 26, 2013, $80M — ARCH Venture Partners, New Mountain Capital, Aravis, Venrock, 5AM Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- New Mountain Capital (https://capitalatlas.ai/funds/new-mountain-capital) — Series A
- Aravis (https://capitalatlas.ai/funds/aravis) — Series A
- Venrock (https://capitalatlas.ai/funds/venrock) — Series A
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A